Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Status:
Terminated
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of fenretinide (4-HPR/LXS) plus
ketoconazole in the treatment of recurrent ovarian cancer or primary peritoneal carcinoma. In
addition, researchers would like to determine if the drugs are most effective together or if
fenretinide (4-HPR/LXS) is most effective alone.